![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/day-one-inks-12b-biobucks-pact-mabcares-solid-tumor-adc
https://www.globenewswire.com/news-release/2024/06/12/2897444/7281/en/XOMA-Receives-8-1-Million-Milestone-Related-to-Day-One-Biopharmaceuticals-Sale-of-its-Priority-Review-Voucher.html
https://www.globenewswire.com/news-release/2024/05/30/2890756/0/en/Day-One-Announces-Sale-of-Priority-Review-Voucher-for-108-Million.html
https://www.globenewswire.com/news-release/2024/05/06/2876191/0/en/Day-One-Reports-First-Quarter-2024-Financial-Results-and-Corporate-Progress.html
https://www.globenewswire.com/news-release/2024/04/29/2871603/0/en/Pediatric-Brain-Tumor-Foundation-celebrates-FDA-approval-of-Day-One-Biopharmaceuticals-OJEMDA-new-treatment-for-common-pediatric-brain-tumor-type.html
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric#:~:text=On%20April%2023%2C%202024%2C%20the,rearrangement%2C%20or%20BRAF%20V600%20mutation.
https://www.globenewswire.com/news-release/2024/04/23/2868089/0/en/Day-One-s-OJEMDA-tovorafenib-Receives-US-FDA-Accelerated-Approval-for-Relapsed-or-Refractory-BRAF-altered-Pediatric-Low-Grade-Glioma-pLGG-the-Most-Common-Form-of-Childhood-Brain-Tu.html
https://ir.dayonebio.com/news-releases/news-release-details/day-ones-ojemdatm-tovorafenib-receives-us-fda-accelerated
https://www.globenewswire.com//news-release/2024/02/26/2835523/0/en/Day-One-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Progress.html
https://www.globenewswire.com//news-release/2024/01/17/2810655/0/en/Day-One-Announces-Two-New-Appointments-to-Board-of-Directors.html